MSLN and neoplasm: Anetumab-ravtansine binds to mesothelin on tumor cells, cleaves the disulfide linker, and internalizes the drug to release DM4, followed by DM4 binding to tubulin, which prevents microtubule polymerization, and causes apoptosis subsequent cell cycle arrest.